LENZ

We are excited to kick off our 2022 convention year in Waikoloa Beach for the Hawaiian Eye & Retina conference. Visit our booth #116. Learn more about LENZ Therapeutics here: lenz-tx.com #HawaiianEyeMeeting

Thank you for following us on our journey to provide best-in-class presbyopia treatment. 2021 was exciting for the LENZ team, with many milestones achieved. Read our full newsletter to learn about our major events here: lnkd.in/dprmYXCN

We are thrilled to announce the addition of Kathryn Hatch, to our Medical Advisory Board. Kathryn is the Director of Refractive Surgery at Massachusetts Eye and Ear and is an Assistant Professor at Harvard Medical School. Learn more about the LENZ team: lnkd.in/e_Qz_uT

Join us in welcoming Kat Simonovic as Marketing Manager at LENZ Therapeutics. Learn more about LENZ Therapeutics at lenz-tx.com #presbyopia

Today at Eyecelerator, we shared the details of LNZ100 and LNZ101, our preservative-free eye drop candidates for the treatment of Presbyopia. Our planned Phase 3 start is 2Q 2022.

We had a great week at #Academy21, looking forward to Eyecelerator and American Academy of Ophthalmology in New Orleans next week! Come visit our presentations and stop by booth #5044. Learn more about LENZ Therapeutics here: lenz-tx.com #presbyopia #biotech

A very successful presentation this morning at the #Academy21. CEO of LENZ Therapeutics, Eef Schimmelpennink and Chief Medical Officer, Marc G. Odrich, MD presented on Presbyopia: Aceclidine and its Unique MOA. Stop by our booth #213 to learn more!

Great presentation at Eyecelerator by Eef Schimmelpennink of LENZ on why Aceclidine's mode of action is different from other miotics #Eyecelerator #ascrs2021 #presbyopia

Enjoyed ASCRS with Terry Kim, MD, recent ASCRS President and LENZ Therapeutics Medical Advisory Board Member for our lead presbyopia eye drop candidate #ASCRS2021 #Presbyopia visit us at lenz-tx.com

Don't miss this week's #BioTuesdays feature with Eef Schimmelpennink, President and CEO of LENZ Therapeutics #presbyopia Read the full article: biotuesdays.com/2021/07/27/len…

LENZ Therapeutics debuts with $47 Million Series A Financing lenz-tx.com/2021/06/lenz_t…